BioNTech & Genmab Partnership
Over the weekend, the collaboration between BioNTech (NASDAQ: BNTX) and Genmab (GMAB) gave rise to a game-changing revelation in the realm of cancer treatment. The two pharmaceutical powerhouses unveiled promising data on the investigational bispecific antibody, acasunlimab. This groundbreaking therapy, when paired with Merck’s (MRK) Keytruda, demonstrated a remarkable enhancement in survival rates among lung cancer patients.
Promising Results
The preliminary findings from a mid-stage trial of acasunlimab in conjunction with Keytruda are nothing short of extraordinary. The therapy regime, with a dosing interval of once every six weeks, delivered a staggering median overall survival (mOS) of 17.5 months. The results stand in sharp contrast to the mOS rates of 5.5 months for acasunlimab monotherapy and 8.6 months for the acasunlimab + pembrolizumab combination administered every three weeks.
Encouraging Survival Rates
Further illuminating the efficacy of this treatment, the study revealed a 12-month overall survival rate of 69% among patients who received the drug combination at the six-week dosing schedule. This positive outcome was based on an interim analysis of an ongoing Phase 2 trial involving 113 patients with PD-L(1)-positive metastatic non-small cell lung cancer.
Promising Safety Profile
The assessment of the experimental therapy accentuated its tolerability, aligning closely with the established safety profiles of the individual drugs. Notably, most of the treatment-related adverse events were categorized as Grade 1 and 2, underscoring the manageable nature of any potential side effects.